Literature DB >> 8262546

Clonal variations in complement activation and deposition of C3b and C4b on model immune complexes.

I Yokoyama1, F Waxman.   

Abstract

This study examined the relationship between complement activation and the deposition of C3b and C4b on a panel of model immune complexes (IC). IC were constructed by combining murine monoclonal IgM, IgA, IgG1, IgG2a or IgG3 anti-dinitrophenyl (DNP) antibodies with DNP-bovine serum albumin (DNP-BSA). The IC were incubated with human plasma as a complement source and the formation of C4a and C3a, as well as the deposition of C4b and C3b on the IC, measured by radioimmunoassay. The results indicate that there were isotype-independent variations in the capacity of different types of IC to activate the classical pathway, especially for isotype-matched pairs of IC containing IgG1, IgG2a and IgG3 antibodies. In most cases, there was a direct relationship between classical pathway activation and the cleavage of C3. There was, for most of the IC, a direct correlation between cleavage of C4 and C3 and the subsequent deposition of C4b and C3b on the IC. However, a pair of IC constructed with independently derived IgG1 antibodies was virtually identical with respect to C3 cleavage and yet differed in the number of C3b molecules deposited on the IC. Collectively, these data suggest that the immunoglobulin variable region can play a significant role in both complement activation and the deposition of C3b and C4b on IC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262546      PMCID: PMC1422188     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Complement-fixing IgG1 constitutes a new subclass of mouse IgG.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Nature       Date:  1979-10-11       Impact factor: 49.962

2.  Alteration in H chain V region affects complement activation by chimeric antibodies.

Authors:  C Horgan; K Brown; S H Pincus
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

3.  A new complement function: solubilization of antigen-antibody aggregates.

Authors:  G W Miller; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

4.  Effect of H chain V region on complement activation by immobilized immune complexes.

Authors:  C Horgan; K Brown; S H Pincus
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

5.  The activation of C3 and C4 in human serum by immune complexes containing mouse monoclonal antibodies of different isotype and affinity: effects on solubilisation.

Authors:  W W Stewart; A Johnson; M W Steward; K Whaley; M A Kerr
Journal:  Mol Immunol       Date:  1988-12       Impact factor: 4.407

6.  The assembly of early components of complement on antibody-antigen aggregates and on antibody-coated erythrocytes.

Authors:  J W Goers; R R Porter
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

7.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

8.  Isotypic and clonal variations in the interactions between model monoclonal immune complexes and the human erythrocyte CR1 receptor.

Authors:  I Yokoyama; F Waxman
Journal:  Mol Immunol       Date:  1992 Jul-Aug       Impact factor: 4.407

9.  Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes.

Authors:  D D Yaskanin; L F Thompson; F J Waxman
Journal:  Cell Immunol       Date:  1992-06       Impact factor: 4.868

10.  Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.

Authors:  L B Klickstein; T J Bartow; V Miletic; L D Rabson; J A Smith; D T Fearon
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  1 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.